Antithyroid Medications and Radioactive Iodine
Antithyroid medications and radioactive iodine (RAI) therapy represent two of the three primary non-surgical treatment modalities for hyperthyroidism, the third being thyroidectomy. Both approaches target excess thyroid hormone production but operate through distinct mechanisms, carry different risk profiles, and suit different patient populations. Understanding the classification, pharmacology, and clinical decision framework for these treatments is foundational to the broader endocrinology practice landscape.
Definition and scope
Antithyroid drugs (ATDs) are a class of thionamide compounds that suppress thyroid hormone synthesis. The two agents approved by the U.S. Food and Drug Administration (FDA) for clinical use are methimazole (MMI) and propylthiouracil (PTU). A third thionamide, carbimazole, is used in the United Kingdom and parts of Europe but is not FDA-approved; it acts as a prodrug that converts to methimazole after absorption.
Radioactive iodine therapy uses iodine-131 (¹³¹I), a beta- and gamma-emitting radioisotope with a physical half-life of approximately 8.02 days. When administered orally, ¹³¹I is concentrated selectively in thyroid follicular cells via the sodium-iodide symporter (NIS), delivering targeted radiation that ablates or reduces thyroid tissue. The Nuclear Regulatory Commission (NRC) and Agreement State programs regulate the administration, patient release criteria, and radiation safety protocols for ¹³¹I therapy under 10 CFR Part 35.
Both treatment categories are deployed within the management of hyperthyroidism and Graves' disease, toxic multinodular goiter, and toxic adenoma. The American Thyroid Association (ATA) publishes evidence-based guidelines — most recently updated in 2016 — that establish the clinical framework for selecting among ATDs, RAI, and surgery.
How it works
Methimazole and PTU — mechanism of action
Both thionamides inhibit thyroid peroxidase (TPO), the enzyme responsible for oxidizing iodide and coupling iodotyrosines to form thyroxine (T4) and triiodothyronine (T3). PTU carries an additional mechanism: at doses above 450 mg/day, it inhibits peripheral conversion of T4 to the more biologically active T3 by blocking type 1 deiodinase. This secondary action makes PTU the preferred agent in thyroid storm, where rapid reduction of T3 levels is a clinical priority.
Key pharmacokinetic distinctions between the two agents:
- Dosing frequency — Methimazole has a longer half-life (~6–13 hours) and is dosed once or twice daily; PTU has a half-life of approximately 1–2 hours and requires dosing every 6–8 hours.
- Potency ratio — Methimazole is roughly 10–20 times more potent by weight than PTU on a milligram-to-milligram basis.
- Placental transfer — Both drugs cross the placenta, but PTU crosses less readily, making it the preferred agent during the first trimester of pregnancy.
- Hepatotoxicity risk — PTU carries an FDA black box warning for severe hepatotoxicity, including fulminant hepatic failure; methimazole does not carry this warning.
Radioactive iodine — mechanism of action
After oral administration of ¹³¹I (typically as sodium iodide solution or capsule), thyroid follicular cells concentrate the isotope through the same NIS transporter used for dietary iodine. Beta radiation from ¹³¹I penetrates tissue approximately 0.5–2 mm, causing DNA strand breaks in follicular cells, cellular necrosis, and fibrosis over 6–18 weeks post-treatment. The result is a permanent reduction in functional thyroid tissue. A single RAI dose achieves euthyroidism or hypothyroidism in approximately 80–90% of patients with Graves' disease, according to the American Thyroid Association 2016 Guidelines.
Common scenarios
ATDs and RAI are used in overlapping but distinct clinical contexts:
- Graves' disease in adults — All three definitive therapies (ATDs, RAI, surgery) are considered first-line by ATA guidelines. ATDs are preferred when remission is the goal, particularly in patients with mild-to-moderate disease and small goiters. Remission rates with an 18-month ATD course range from approximately 30–50% in North American populations.
- Graves' disease in pregnancy — RAI is absolutely contraindicated throughout pregnancy and for 4–6 months prior to planned conception due to fetal thyroid irradiation risk. PTU is the standard in the first trimester; methimazole is preferred from the second trimester onward due to PTU hepatotoxicity concerns.
- Toxic multinodular goiter (MNG) and toxic adenoma — RAI is frequently preferred because spontaneous remission does not occur with these autonomous nodules. ATDs can achieve biochemical control but do not produce lasting remission.
- Preparation for RAI — ATDs, particularly methimazole, are often used to normalize thyroid function before RAI administration to reduce the risk of radiation thyroiditis and thyroid storm in elderly patients or those with cardiovascular comorbidities.
- Pediatric hyperthyroidism — The regulatory and clinical context for endocrinology recognizes that RAI use in children under 10 years of age is generally avoided given theoretical cancer risk; methimazole is the primary long-term medical option.
Decision boundaries
The ATA and the European Thyroid Association (ETA) identify several clinical variables that guide treatment selection:
| Factor | Favors ATD | Favors RAI |
|---|---|---|
| Desire for remission | Yes (18–24 month trial) | No (ablative intent) |
| Pregnancy or near-term plans | Yes (PTU/MMI as appropriate) | Contraindicated |
| Large goiter with compressive symptoms | No | No (surgery preferred) |
| Severe ophthalmopathy (Graves') | Yes | Relative contraindication |
| Agranulocytosis history from ATDs | No | Yes |
| Age under 10 years | Yes | Generally avoided |
| Non-compliance risk | No | Yes (single-dose modality) |
Agranulocytosis — an absolute neutrophil count below 500 cells/μL — is the most serious hematologic adverse effect of thionamide therapy, occurring in approximately 0.1–0.5% of patients (ATA Guidelines, 2016). Patients must be instructed to discontinue ATDs and seek immediate evaluation for fever or sore throat, as this symptom pattern is the classic presentation.
For RAI, radiation safety regulations under NRC 10 CFR Part 35 require that administered doses to outpatients not result in total effective dose equivalents exceeding 5 millisieverts (mSv) to any individual member of the public, governing patient release and isolation instructions post-treatment.
References
- American Thyroid Association (ATA) — 2016 Guidelines for Diagnosis and Management of Hyperthyroidism
- U.S. Nuclear Regulatory Commission — 10 CFR Part 35: Medical Use of Byproduct Material
- U.S. Food and Drug Administration (FDA) — Drug Safety Communication: Propylthiouracil
- European Thyroid Association (ETA) — Clinical Practice Guidelines
- National Institutes of Health MedlinePlus — Radioactive Iodine Therapy
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)